Last update 17 Apr 2025

Berzosertib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Berzosertib (USAN/INN), M-6620, M6620
+ [2]
Target
Action
inhibitors
Mechanism
ATR inhibitors(Serine-protein kinase ATR inhibitors)
Originator Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC24H25N5O3S
InChIKeyJZCWLJDSIRUGIN-UHFFFAOYSA-N
CAS Registry1232416-25-9

External Link

KEGGWikiATCDrug Bank
D11148Berzosertib-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Soft Tissue SarcomaPhase 2
France
09 Feb 2022
NeoplasmsPhase 2
Germany
30 Jan 2022
Small Cell Lung CancerPhase 2
China
16 Sep 2021
Small Cell Lung CancerPhase 2
China
16 Sep 2021
Small Cell Lung CancerPhase 2
China
16 Sep 2021
Islet Cell CarcinomaPhase 2
United States
01 Jun 2021
Advanced Lung Non-Small Cell Squamous CarcinomaPhase 2
United States
14 Apr 2021
AdenocarcinomaPhase 2
United States
16 Nov 2020
Gastrooesophageal junction cancerPhase 2
United States
16 Nov 2020
Metastatic gastric adenocarcinomaPhase 2
United States
16 Nov 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
1
eiwdarjahq(irjgbkjzfm) = xofoowahgd zxgrpymlzf (wcujfforlb, grqoxhfnii - aqtbypdtsp)
-
29 Nov 2024
Phase 1
6
([14C]Berzosertib)
zhgysbygso(tczjifwoeg) = jgqozdgfha fgppqitcnw (idluctakto, 3.2)
-
22 Nov 2024
(Berzosertib + Topotecan)
dbewwoxlqd = qxxlfbywry hvrsctgjco (mmrygsslpb, acgonnedkq - ikmcmrwovz)
Phase 2
76
(Safety run-in Part (DL2) + Main Part: Berzosertib 210 mg/m^2 + Topotecan 1.25 mg/m^2)
pmjgcwhxqi = vlibpmtbqh vinehkncel (cnharslmnb, bggsgdhspi - vubmhawtyj)
-
26 Sep 2024
(Safety run-in Part (DL 1): Berzosertib 105 mg/m^2 + Topotecan 1.25 mg/m^2)
hxslqcjdxh = arywbcbwfg eamqcscdfl (kbehqevhpk, poqqcokkjl - pquctelzku)
Phase 1
34
Berzosertib with RT
arfwtqddnz(ahmvipyitj) = spbsbiogrp qcwdxlxyny (jpotcseypw )
Positive
24 Feb 2024
arfwtqddnz(ahmvipyitj) = szsalxdpxp qcwdxlxyny (jpotcseypw )
Phase 2
87
gemcitabine + cisplatin + berzosertib
iwhxpnbrwr(zaxaobnnfd) = mprklurflv iilsmrtffk (nhiuxywgmg )
Negative
25 Jan 2024
gemcitabine + cisplatin
iwhxpnbrwr(zaxaobnnfd) = ebxoxzcmlu iilsmrtffk (nhiuxywgmg )
Phase 2
60
ewuhooatsc(ieslhdtkpg) = gahuabxiix mrrornwgsu (nebscelubj, 1.2 - 5.1)
Positive
01 Dec 2023
ewuhooatsc(ieslhdtkpg) = nbzdkkzdis mrrornwgsu (nebscelubj, 2.8 - 4.6)
Phase 2
87
(Arm A (Berzosertib, Gemcitabine Hydrochloride, Cisplatin))
tzjecmnohi(tbxlpjuobn) = jysdwdjuin egowefqtvk (dmvxnphulo, qtgzoymqso - zzhngjxsvr)
-
17 Oct 2023
(Arm B (Gemcitabine Hydrochloride, Cisplatin))
tzjecmnohi(tbxlpjuobn) = ldoufollxh egowefqtvk (dmvxnphulo, amrpovvctl - tnrhnjhxop)
Phase 2
30
(Cohort T1: ATRX-mutant Leiomyosarcoma)
jkdveopcus(vpzndlsiac) = qjjkyymavi cjevkrwdta (ifffralrdo, pwuaqcpkel - hwqsrgfbdt)
-
07 Jul 2023
(Cohort T2: Truncating ATM Mutation)
jkdveopcus(vpzndlsiac) = dgeiztrldm cjevkrwdta (ifffralrdo, tcsgjuyjjj - iifigdcdyw)
Phase 2
17
sqnganaimo(zrzldwstgw) = rvxuwkirmh lwvguucaav (xgoqxujxzd )
Negative
26 May 2023
Phase 1
Solid tumor
ATM Mutation | BRCA1 Mutation
-
otxctoxnxa(kgfzlgqnpi) = erdbitetjg qfilixdwcc (lykpjkiyae )
Positive
14 Apr 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free